BioCentury
ARTICLE | Clinical News

Merck reports additional data for CETP inhibitor in CHD

September 1, 2017 7:56 PM UTC

Merck & Co. Inc. (NYSE:MRK) reported additional data from the Phase III REVEAL trial in patients with atherosclerotic vascular disease showing that once-daily 100 mg oral anacetrapib (MK-0859) reduced major coronary events -- the primary endpoint defined as a composite of coronary death, myocardial infarction (MI) or coronary revascularization -- by 9% compared to placebo (1,640 vs. 1,803 events, p=0.004). Merck previously reported that the cholesteryl ester transfer protein (CETP) inhibitor met the primary endpoint (see BioCentury, July 6).

An analysis of the individual components of the primary endpoint showed that compared to placebo, anacetrapib significantly reduced the risk of MI (HR=0.87, p=0.007), but not coronary death (HR=0.92, p=0.25). The rate of coronary revascularization was significantly lower in the anacetrapib group vs. placebo (HR=0.9, p=0.01)...

BCIQ Company Profiles

Merck & Co. Inc.